KP1019 C화학적 특성, 용도, 생산
Pharmaceutical Applications
KP1019 is active against
primary cancers, whereas NAMI-A is active against metastasis, secondary tumours that have moved to other
areas. The treatment of metastasis is currently an area where improvement is urgently needed.KP1019, trans-[tetrachloro-bis(1H-indazole)ruthenate(III)], was tested in phase I clinical trials as a possible
treatment option against colon cancer. Administered doses ranged from 25 to 600 mg twice weekly,
and no significant side effects were noticed. The synthesis of KP1019 also starts with RuCl
3·3H
20, which is
dissolved in ethanolic HCl and reacted with an excess of indazole .
KP1019 준비 용품 및 원자재
원자재
준비 용품
